If the release of CXCL13 could occur in vivo, it could promote the onset of B cell lymphomas, malignancies that indeed more frequently arise in patients suffering of IBD (Nissen et al., 2015). Here, CXCL13 is linked to B-cell non-Hodgkin lymphoma.